The investment objective of the C WorldWide Biotechnology fund is to seek capital growth by investing in equities in the biotechnology/bioscience area, including companies with activities in the areas of drug delivery, drug discovery, therapeutics, enabling technologies and diagnostics. Biotech is a research-intensive sector currently in an era of new discoveries and scientific progress. The strategy invests primarily in fast-growing smaller research and pharma companies, which are underanalyzed compared to the bigger ones and consequently more difficult to value. Patent expirations among the bigger companies drive demand. Expiring patents lead to shrinking profits and in order to compensate for this, new products are needed. Smaller biotech companies with drugs under development benefit from this, and the number of new drugs under development is steadily increasing. The fund may be leveraged up to 25 per cent of the value of its net assets for investment purposes.
|C WorldWide Biotechnology||Benchmark|
TOP 10 HOLDINGS
|Share in %|
|Gilead Sciences||7.1 %|
|Vertex Pharmaceuticals||6.6 %|
|Biomarin Pharma||4.7 %|
|Jazz Pharmaceuticals||3.6 %|
|Alexion Pharmaceuticals||2.8 %|
|Clovis Oncology||2.6 %|
RETURN & RISK
|1 Y||3 Y||5 Y||10 Y||Lifetime||P.A.|
|C WorldWide Biotechnology (%)||3.8||6.2||15.5||11.1||6.1||6.1|
|Relative performance (%)||2.5||-7.5||-5.7||-4.8||2.5||2.5|
|3 Y||5 Y||10 Y||Lifetime||P.A.|
|Std. dev. portfolio (%)||31.9||28.8||23.8||26.2||26.2|
|Std. dev. benchmark (%)||27.0||25.5||22.0||26.0||26.0|
|Security identifier (ISIN):||LU0119485372|
|Launch date:||8 November 2000|
|Management fee:||1.10% per annum|
|Minimum investment:||EUR 1,000|
|Benchmark:||NASDAQ Biotechnology Index®|
|NAV at month end:||26.77|
|Fund AUM:||10.0 million|
|Investment Manager:||C WorldWide Asset Management, Stockholm|
|Portfolio Manager:||Ulf Arvidsson|
The fact sheet is for information purposes only. The fact sheet does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any fund. The information, calculations etc. shall not be considered investment advice or requests to engage in investment operations.
All reasonable precautions have been taken to ensure the correctness and accuracy of the fact sheet. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions.
It is emphasized that the figures in the fact sheet are historical, and that past performance is no reliable indicator of future performance.